Hepatitis A News and Research

RSS

Hepatitis A (formerly known as ''infectious hepatitis'') is an acute infectious disease of the liver caused by the hepatitis A virus (HAV), which is most commonly transmitted by the fecal-oral route via contaminated food or drinking water.

New virus drug will have to shoot at moving targets

The reproduction of

22 Oct 2007

Implicit wins $16.3 million U.S. government contract to develop its clinical stage drug oglufanide disodium

Implicit Bioscience has announced that it has been awarded a US$16.34 million (AU$18.2million) contract payable over 37 months from the United States Defense Threat Reduction Agency (DTRA) to develop its clinical stage drug oglufanide disodium as a broad spectrum therapeutic for the treatment of a number of intracellularbacterial diseases.

22 Oct 2007

T-cell exhaustion

A new study of immune cells battling a chronic viral infection shows that the cells, called T cells, become exhausted by the fight in specific ways, undergoing profound changes that make them progressively less effective over time.

19 Oct 2007

New mechanism discovered that mammalian cells employ to fight infections of the Hepatitis C virus

A team of researchers led by biologists at the University of California, San Diego has discovered a completely new mechanism that mammalian cells employ to fight infections of the Hepatitis C virus, which affects approximately 2.7 million Americans and 170 million people worldwide.

18 Oct 2007

Liver fibrosis will be treated by a potential target

The outcome of hepatitis is either self recovery or its development into liver fibrosis or, further, liver cirrhosis.

17 Oct 2007

Over 2 decades experiences shows that ultrasound-guided liver biopsy is the procedure of choice

Liver biopsy is a widely used tool in the investigation of liver diseases. It is invasive and has a mortality risk ranging between 0.01% and 0.17%. A liver biopsy should therefore only be performed in patients who would potentially benefit from it.

16 Oct 2007

Can liver cirrhosis be partially cured?

The diffusion of hepatitis C virus infection worldwide is astonishing. Liver cirrhosis is present in at least 10-20% of these infected patients, with highly increasing health care and emotional costs.

10 Oct 2007

Combination vaccine OK for toddlers

A University of Rochester study brings relief to new parents who, while navigating a jam-packed childhood vaccine schedule, can expect to soothe their newborn through as many as 15 "pokes" by his or her six-month checkup.

8 Oct 2007

Osteoarthritis drug Prexige withdrawn from Canadian market

Health authorities in Canada have withdrawn the osteoarthritis drug Prexige from the market amid concerns the drug increases the risk for serious liver-related damage including hepatitis.

4 Oct 2007

Vaccine combo okay for infants

4 Oct 2007

Irish Government launches program to provide life insurance to people with HIV, Hep C through contaminated blood products

The Irish government on Thursday launched a program to provide life insurance, mortgage protection and travel insurance to people who contracted HIV or hepatitis C through contaminated blood products, Ireland's Evening Echo reports (Evening Echo, 9/27).

2 Oct 2007

Judge acquits Canadian doctors, U.S. drug company in tainted blood case

A Canadian judge on Monday acquitted New Jersey-based Armour Pharmaceutical Company and four Canadian doctors -- including the former medical director of the Canadian Red Cross and two government officials -- of charges related to blood products contaminated with HIV and hepatitis C, the New York Times reports (Austen, New York Times, 10/2).

2 Oct 2007

Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C

Patients with hepatitis C treated with combination therapy of pegylated interferon and ribavirin had better outcomes when taking a weight-based dosage of ribavirin compared to a flat dosage.

2 Oct 2007

New way to fight hepatitis B

One in four people who are chronically infected with hepatitis B will die from its impact if untreated, but a team of researchers at the Stanford University School of Medicine has identified the most cost-effective way of fighting this treacherous infection.

2 Oct 2007

Noninvasive tests for cirrhosis may help to avoid liver biopsy

Newer ultrasound and magnetic resonance (MR) imaging tests yield encouraging initial results in diagnosing fibrosis (scarring) and cirrhosis of the liver, according to three studies in the October issue of the journal Clinical Gastroenterology and Hepatology.

2 Oct 2007

Majority of Europeans with hepatitis C remain undiagnosed

A report by the Eurasian Harm Reduction Network (EHRN highlights the significant inconsistencies that exist in hepatitis C (HCV) diagnosis and treatment across Europe and beyond. In recognition of World Hepatitis Awareness Day, patient groups around the globe are united in their call for action.

1 Oct 2007

CDC awards $35 million to increase HIV testing opportunities

The Centers for Disease Control and Prevention has awarded $35 million in funding to state and local health departments to increase HIV testing opportunities among populations disproportionately affected by HIV, primarily African Americans.

27 Sep 2007

Manipulating immune response provides new approach to liver failure

If the results of the animal study can be applied in human patients, the approach may be able to keep patients alive until donor organs become available or to support liver function until the organ can regenerate itself, eliminating the need for a transplant.

25 Sep 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

New topical lotion safely treats nail fungus without side effects

A new topical lotion that penetrates the skin deeply enough to target and eliminate serious skin infections, but without being systemically absorbed, has shown a high degree of safety and tolerability in patients with onychomycosis, or toenail fungus, a new study has shown.

25 Sep 2007